Stryker Corporation $SYK Shares Sold by US Bancorp DE

US Bancorp DE trimmed its stake in Stryker Corporation (NYSE:SYK) by 0.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 172,485 shares of the medical technology company’s stock after selling 1,467 shares during the quarter. US Bancorp DE’s holdings in Stryker were worth $63,764,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth $26,000. Elevation Point Wealth Partners LLC purchased a new stake in Stryker during the second quarter valued at about $28,000. Kilter Group LLC acquired a new stake in Stryker during the second quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Stryker during the second quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker in the 3rd quarter worth about $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on SYK shares. Evercore set a $390.00 target price on shares of Stryker in a research report on Monday, January 5th. BTIG Research increased their price objective on shares of Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a report on Tuesday, January 6th. Sanford C. Bernstein upped their price target on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Finally, Wells Fargo & Company raised their price objective on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Thirteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $426.47.

Stryker Stock Up 0.5%

Shares of Stryker stock opened at $386.04 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $404.87. The business has a 50-day moving average of $362.53 and a 200-day moving average of $369.14. The company has a market capitalization of $147.73 billion, a PE ratio of 45.96, a P/E/G ratio of 2.24 and a beta of 0.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter last year, the firm earned $4.01 EPS. Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is currently 41.90%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.